PE20150670A1 - Sal de tipo camsilato - Google Patents

Sal de tipo camsilato

Info

Publication number: PE20150670A1
Authority: PE; Peru
Prior art keywords: dementia; salt; disease; camsilate; type salt
Prior art date: 2012-06-21

Application number

PE2014002451A

Other languages

English (en)

Spanish (es)

Inventor

Martin Hans Bohlin

Craig Robert Stewart

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-21

Filing date

2013-06-20

Publication date

2015-06-03

2013-06-20 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2015-06-03 Publication of PE20150670A1 publication Critical patent/PE20150670A1/es

Links

150000003839 salts Chemical class 0.000 title abstract 3
229950005953 camsilate Drugs 0.000 title 1
208000024827 Alzheimer disease Diseases 0.000 abstract 3
206010012289 Dementia Diseases 0.000 abstract 3
102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
206010059245 Angiopathy Diseases 0.000 abstract 1
201000010374 Down Syndrome Diseases 0.000 abstract 1
206010033799 Paralysis Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
206010036631 Presenile dementia Diseases 0.000 abstract 1
206010039966 Senile dementia Diseases 0.000 abstract 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 abstract 1
230000007850 degeneration Effects 0.000 abstract 1
230000003412 degenerative effect Effects 0.000 abstract 1
230000007170 pathology Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000000750 progressive effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PE2014002451A 2012-06-21 2013-06-20 Sal de tipo camsilato PE20150670A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261662592P	2012-06-21	2012-06-21

Publications (1)

Publication Number	Publication Date
PE20150670A1 true PE20150670A1 (es)	2015-06-03

Family

ID=48746084

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2014002451A PE20150670A1 (es)	2012-06-21	2013-06-20	Sal de tipo camsilato

Country Status (42)

Country	Link
US (1)	US10548882B2 (2)
EP (2)	EP2864316B1 (2)
JP (2)	JP2015520221A (2)
KR (1)	KR102123708B1 (2)
CN (2)	CN106279102A (2)
AP (2)	AP2014008137A0 (2)
AR (2)	AR091495A1 (2)
AU (2)	AU2013279109B2 (2)
BR (2)	BR122016014302B1 (2)
CA (1)	CA2875589C (2)
CL (1)	CL2014003374A1 (2)
CO (1)	CO7151486A2 (2)
CR (2)	CR20140571A (2)
CY (1)	CY1119505T1 (2)
DK (1)	DK2864316T3 (2)
DO (1)	DOP2014000268A (2)
EC (1)	ECSP14032215A (2)
ES (1)	ES2618939T3 (2)
HR (1)	HRP20170359T1 (2)
HU (1)	HUE033376T2 (2)
IL (1)	IL236131A0 (2)
IN (1)	IN2014DN10088A (2)
LT (1)	LT2864316T (2)
MA (2)	MA39259B1 (2)
ME (1)	ME02633B (2)
MX (1)	MX354214B (2)
NI (1)	NI201400146A (2)
NZ (2)	NZ702742A (2)
PE (1)	PE20150670A1 (2)
PH (2)	PH12014502803A1 (2)
PL (1)	PL2864316T3 (2)
PT (1)	PT2864316T (2)
RS (1)	RS55815B1 (2)
RU (1)	RU2638175C2 (2)
SG (1)	SG11201407934UA (2)
SI (1)	SI2864316T1 (2)
SM (1)	SMT201700142T1 (2)
TN (1)	TN2014000491A1 (2)
TW (2)	TWI588140B (2)
UA (1)	UA114196C2 (2)
WO (1)	WO2013190302A1 (2)
ZA (1)	ZA201500408B (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8415483B2 (en)	2010-12-22	2013-04-09	Astrazeneca Ab	Compounds and their use as BACE inhibitors
US9650336B2 (en)	2011-10-10	2017-05-16	Astrazeneca Ab	Mono-fluoro beta-secretase inhibitors
US9000184B2 (en)	2012-06-20	2015-04-07	Astrazeneca Ab	Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000183B2 (en)	2012-06-20	2015-04-07	Astrazeneca Ab	Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en)	2012-06-20	2015-04-07	Astrazeneca Ab	Cycloalkyl ether compounds and their use as BACE inhibitors
US9000182B2 (en)	2012-06-20	2015-04-07	Astrazeneca Ab	2H-imidazol-4-amine compounds and their use as BACE inhibitors
WO2016055858A1 (en)	2014-10-07	2016-04-14	Astrazeneca Ab	Compounds and their use as bace inhibitors
JP6546410B2 (ja) *	2015-02-23	2019-07-17	ローム株式会社	電力供給装置、ａｃアダプタ、ａｃチャージャ、電子機器および電力供給システム
AR107783A1 (es) *	2016-03-15	2018-06-06	Lilly Co Eli	Terapia de combinación
WO2017158064A1 (en)	2016-03-15	2017-09-21	Astrazeneca Ab	Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
WO2020183021A1 (en)	2019-03-14	2020-09-17	Astrazeneca Ab	Lanabecestat for weight loss

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100452491B1 (ko) *	2001-03-29	2004-10-12	한미약품 주식회사	신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
WO2002098462A1 (en)	2001-06-01	2002-12-12	Ono Pharmaceutical Co., Ltd.	Remedies containing aldose reductase inhibitor as the active ingredient for demyelinating diseases or diseases associated with demyelination
US7592348B2 (en)	2003-12-15	2009-09-22	Schering Corporation	Heterocyclic aspartyl protease inhibitors
DE602005017129D1 (de)	2004-03-22	2009-11-26	Lilly Co Eli	Pyridyl-derivate und ihre verwendung als mglu5-rezeptorantagonisten
PE20070135A1 (es)	2005-06-14	2007-03-09	Schering Corp	Compuestos heterociclicos como inhibidores de aspartil proteasas
WO2007058601A1 (en)	2005-11-21	2007-05-24	Astrazeneca Ab	Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
TW200734311A (en)	2005-11-21	2007-09-16	Astrazeneca Ab	New compounds
JP2009521488A (ja)	2005-12-21	2009-06-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｐｋｃ−シータのインヒビターとして有益なピリミジン誘導体
WO2007100536A1 (en)	2006-02-24	2007-09-07	Wyeth	DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
PE20080155A1 (es)	2006-06-12	2008-03-10	Schering Corp	Compuestos heterociclicos como inhibidores de aspartil-proteasa
WO2008076044A1 (en)	2006-12-20	2008-06-26	Astrazeneca Ab	Novel 2-amino-5, 5-diaryl-imidazol-4-ones
WO2008092877A2 (en)	2007-02-01	2008-08-07	Glaxo Group Limited	8-oxa-1, 4-diazaspiro [4,5] dec-3-en-1-yl and 1,4, 8-triazaspiro [4,5] dec- 3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
RU2009144998A (ru)	2007-05-07	2011-06-20	Шеринг Корпорейшн (US)	Модуляторы гамма-секретазы
WO2009100169A1 (en)	2008-02-06	2009-08-13	Glaxo Group Limited	Dual pharmacophores - pde4-muscarinic antagonistics
FR2929943B1 (fr) *	2008-04-15	2010-09-24	Inst Rech Developpement Ird	Sels de quinoleines 2-substituees
CN102105475B (zh)	2008-07-28	2014-04-09	卫材R&D管理有限公司	螺氨基二氢噻嗪衍生物
WO2010021680A2 (en)	2008-08-19	2010-02-25	Vitae Pharmaceuticals, Inc.	Inhibitors of beta-secretase
MY148558A (en)	2008-09-11	2013-04-30	Amgen Inc	Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
MX2011009571A (es)	2009-03-13	2011-10-19	Boehringer Ingelheim Int	Inhibidores de beta-secretasa.
AR077447A1 (es)	2009-07-02	2011-08-31	Astrazeneca Ab	Compuestos inhibidores de beta-secretasa, utiles para el tratamiento de enfermedades neurodegenerativas
UY32750A (es)	2009-07-02	2011-01-31	Astrazeneca Ab	Imidazoles sustituidos y uso de los mismos
JP5828848B2 (ja)	2010-02-24	2015-12-09	ヴァイティーファーマシューティカルズ，インコーポレイテッド	ベータセクレターゼインヒビター
US20120065195A1 (en)	2010-03-31	2012-03-15	Clark Christopher T	Compounds for treating neurodegenerative diseases
WO2011130741A1 (en)	2010-04-16	2011-10-20	Array Biopharma Inc.	Compounds for treating neurodegenerative diseases
US8921363B2 (en)	2010-08-05	2014-12-30	Amgen Inc.	Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
TW201219400A (en)	2010-09-24	2012-05-16	Array Biopharma Inc	Compounds for treating neurodegenerative diseases
WO2012071458A1 (en)	2010-11-22	2012-05-31	Array Biopharma Inc.	Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases
US8415483B2 (en) *	2010-12-22	2013-04-09	Astrazeneca Ab	Compounds and their use as BACE inhibitors
US9650336B2 (en)	2011-10-10	2017-05-16	Astrazeneca Ab	Mono-fluoro beta-secretase inhibitors
US9000185B2 (en)	2012-06-20	2015-04-07	Astrazeneca Ab	Cycloalkyl ether compounds and their use as BACE inhibitors
US9000183B2 (en)	2012-06-20	2015-04-07	Astrazeneca Ab	Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000184B2 (en)	2012-06-20	2015-04-07	Astrazeneca Ab	Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en)	2012-06-20	2015-04-07	Astrazeneca Ab	2H-imidazol-4-amine compounds and their use as BACE inhibitors

2013
- 2013-06-13 US US13/916,754 patent/US10548882B2/en active Active
- 2013-06-19 AR ARP130102162 patent/AR091495A1/es unknown
- 2013-06-20 CN CN201610570484.2A patent/CN106279102A/zh active Pending
- 2013-06-20 SG SG11201407934UA patent/SG11201407934UA/en unknown
- 2013-06-20 SI SI201330561A patent/SI2864316T1/sl unknown
- 2013-06-20 PL PL13733415T patent/PL2864316T3/pl unknown
- 2013-06-20 NZ NZ702742A patent/NZ702742A/en not_active IP Right Cessation
- 2013-06-20 EP EP13733415.7A patent/EP2864316B1/en active Active
- 2013-06-20 JP JP2015517850A patent/JP2015520221A/ja active Pending
- 2013-06-20 BR BR122016014302-3A patent/BR122016014302B1/pt active IP Right Grant
- 2013-06-20 CA CA2875589A patent/CA2875589C/en active Active
- 2013-06-20 RS RS20170236A patent/RS55815B1/sr unknown
- 2013-06-20 WO PCT/GB2013/051606 patent/WO2013190302A1/en not_active Ceased
- 2013-06-20 LT LTEP13733415.7T patent/LT2864316T/lt unknown
- 2013-06-20 MX MX2014014709A patent/MX354214B/es active IP Right Grant
- 2013-06-20 AP AP2014008137A patent/AP2014008137A0/xx unknown
- 2013-06-20 AU AU2013279109A patent/AU2013279109B2/en active Active
- 2013-06-20 NZ NZ727045A patent/NZ727045A/en not_active IP Right Cessation
- 2013-06-20 KR KR1020147035069A patent/KR102123708B1/ko active Active
- 2013-06-20 RU RU2014148305A patent/RU2638175C2/ru active
- 2013-06-20 PE PE2014002451A patent/PE20150670A1/es active IP Right Grant
- 2013-06-20 UA UAA201412619 patent/UA114196C2/uk unknown
- 2013-06-20 PT PT137334157T patent/PT2864316T/pt unknown
- 2013-06-20 HU HUE13733415A patent/HUE033376T2/en unknown
- 2013-06-20 AP AP2017009693A patent/AP2017009693A0/en unknown
- 2013-06-20 SM SM20170142T patent/SMT201700142T1/it unknown
- 2013-06-20 HR HRP20170359TT patent/HRP20170359T1/hr unknown
- 2013-06-20 IN IN10088DEN2014 patent/IN2014DN10088A/en unknown
- 2013-06-20 MA MA39259A patent/MA39259B1/fr unknown
- 2013-06-20 ES ES13733415.7T patent/ES2618939T3/es active Active
- 2013-06-20 BR BR112014031531-0A patent/BR112014031531B1/pt active IP Right Grant
- 2013-06-20 DK DK13733415.7T patent/DK2864316T3/en active
- 2013-06-20 CN CN201380033030.6A patent/CN104411697B/zh active Active
- 2013-06-20 EP EP16162104.0A patent/EP3064494A1/en not_active Withdrawn
- 2013-06-21 TW TW102122259A patent/TWI588140B/zh not_active IP Right Cessation
- 2013-06-21 TW TW106115007A patent/TWI639591B/zh not_active IP Right Cessation
2014
- 2014-11-25 DO DO2014000268A patent/DOP2014000268A/es unknown
- 2014-11-25 TN TN2014000491A patent/TN2014000491A1/fr unknown
- 2014-12-08 IL IL236131A patent/IL236131A0/en active IP Right Grant
- 2014-12-10 MA MA37666A patent/MA37666B1/fr unknown
- 2014-12-11 CL CL2014003374A patent/CL2014003374A1/es unknown
- 2014-12-11 CR CR20140571A patent/CR20140571A/es unknown
- 2014-12-16 PH PH12014502803A patent/PH12014502803A1/en unknown
- 2014-12-18 CO CO14278352A patent/CO7151486A2/es unknown
- 2014-12-18 NI NI201400146A patent/NI201400146A/es unknown
- 2014-12-18 EC ECIEPI201432215A patent/ECSP14032215A/es unknown
2015
- 2015-01-20 ZA ZA2015/00408A patent/ZA201500408B/en unknown
2016
- 2016-03-14 PH PH12016500498A patent/PH12016500498A1/en unknown
- 2016-04-29 CR CR20160202A patent/CR20160202A/es unknown
- 2016-06-28 AR ARP160101953A patent/AR105176A2/es unknown
2017
- 2017-03-08 ME MEP-2017-61A patent/ME02633B/me unknown
- 2017-03-13 CY CY20171100314T patent/CY1119505T1/el unknown
- 2017-11-03 AU AU2017254965A patent/AU2017254965B2/en not_active Ceased
2018
- 2018-02-09 JP JP2018021595A patent/JP6509393B2/ja active Active

Also Published As

Publication number	Publication date
LT2864316T (lt)	2017-03-27
EP3064494A1 (en)	2016-09-07
AU2017254965B2 (en)	2019-05-09
JP2015520221A (ja)	2015-07-16
US10548882B2 (en)	2020-02-04
ECSP14032215A (es)	2015-12-31
CR20160202A (es)	2016-07-26
MX2014014709A (es)	2015-03-04
AU2013279109B2 (en)	2017-08-31
CN104411697A (zh)	2015-03-11
MA39259A1 (fr)	2017-12-29
HK1206349A1 (en)	2016-01-08
PH12014502803B1 (en)	2015-02-23
BR122016014302A2 (pt)	2019-08-27
PT2864316T (pt)	2017-02-24
MA37666A1 (fr)	2016-04-29
IL236131A0 (en)	2015-02-01
JP6509393B2 (ja)	2019-05-08
PH12014502803A1 (en)	2015-02-23
WO2013190302A1 (en)	2013-12-27
CN106279102A (zh)	2017-01-04
CY1119505T1 (el)	2018-03-07
UA114196C2 (uk)	2017-05-10
NI201400146A (es)	2016-09-21
AU2013279109A1 (en)	2015-01-15
CA2875589A1 (en)	2013-12-27
DK2864316T3 (en)	2017-03-20
TN2014000491A1 (en)	2016-03-30
BR112014031531B1 (pt)	2022-08-02
EP2864316A1 (en)	2015-04-29
JP2018104448A (ja)	2018-07-05
CR20140571A (es)	2015-02-04
TWI588140B (zh)	2017-06-21
SMT201700142T1 (it)	2017-05-08
MA39259B1 (fr)	2018-09-28
MX354214B (es)	2018-02-19
RS55815B1 (sr)	2017-08-31
SG11201407934UA (en)	2015-01-29
CN104411697B (zh)	2016-08-10
ES2618939T3 (es)	2017-06-22
TW201730177A (zh)	2017-09-01
IN2014DN10088A (2)	2015-08-21
HRP20170359T1 (hr)	2017-05-05
AR091495A1 (es)	2015-02-11
NZ702742A (en)	2016-12-23
AP2014008137A0 (en)	2014-12-31
NZ727045A (en)	2018-06-29
ZA201500408B (en)	2016-10-26
PH12016500498A1 (en)	2017-04-10
TW201406745A (zh)	2014-02-16
ME02633B (me)	2017-06-20
KR102123708B1 (ko)	2020-06-16
EP2864316B1 (en)	2016-12-14
DOP2014000268A (es)	2015-04-15
AP2017009693A0 (en)	2017-01-31
CL2014003374A1 (es)	2015-02-27
BR112014031531A2 (pt)	2017-06-27
TWI639591B (zh)	2018-11-01
CO7151486A2 (es)	2014-12-29
HUE033376T2 (en)	2017-11-28
KR20150023388A (ko)	2015-03-05
MA37666B1 (fr)	2016-12-30
CA2875589C (en)	2020-08-25
BR122016014302B1 (pt)	2022-08-23
SI2864316T1 (sl)	2017-04-26
AR105176A2 (es)	2017-09-13
US20140031379A1 (en)	2014-01-30
RU2014148305A (ru)	2016-08-10
RU2638175C2 (ru)	2017-12-12
AU2017254965A1 (en)	2017-11-23
PL2864316T3 (pl)	2017-09-29

Legal Events

Date	Code	Title	Description
2019-02-07	FG	Grant, registration

Publication	Publication Date	Title
PE20150670A1 (es)	2015-06-03	Sal de tipo camsilato
DOP2013000147A (es)	2013-10-15	Compuestos y su uso como inhibidores de bace
DOP2018000204A (es)	2019-07-15	Moduladores alostéricos de receptores de acetilcolina nicotínicos
CO2017004465A2 (es)	2017-07-19	2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
MX361727B (es)	2018-12-14	Variantes de polipeptido ph20, formulaciones y usos de las mismas.
PE20150631A1 (es)	2015-05-11	Formas cristalinas de un modulador del receptor androgenico
UY33241A (es)	2011-09-30	?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
UY34742A (es)	2013-11-29	Agentes para tratar trastornos que implican la modulación de receptores de rianodina
CO2018005315A2 (es)	2018-08-10	Moduladores de la interacción de sestrina-gator2 y sus usos
ECSP13013120A (es)	2014-02-28	Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
MX2016010777A (es)	2016-10-26	2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer.
BR112013005855A2 (pt)	2016-05-17	heteroarilas fundidas e seus usos
GT201400242A (es)	2015-08-27	"nuevos compuestos de pirazol"
BR112015026967A8 (pt)	2018-01-30	fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
HK1206347A1 (en)	2016-01-08	Cyclohexane-1,2'-naphthalene-1',2"-imidazole compounds and their use as bace inhibitors
UY35158A (es)	2014-07-31	?moduladores selectivos del receptor de andrógenos novedosos?.
BR112013004562A2 (pt)	2016-09-06	2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3
HK1206348A1 (en)	2016-01-08	Cyclohexane-1,2'-indene-1',2"-imidazol compounds and their use as bace inhibitors
CO7160082A2 (es)	2015-01-15	Un método para mejorar la función hepática
CO7160083A2 (es)	2015-01-15	Método de reducción de peso
BR112013004690A2 (pt)	2016-05-10	2-oxo-e 2-tioxo-di-hidroquinolina-3-carboxamidas substituídas como moduladores kcnq2/3
IL234616A0 (en)	2014-11-30	A herbal preparation for the treatment of metabolic diseases
CU20130083A7 (es)	2013-12-11	Compuestos y su uso como inhibidores de bace
BR112015009214A2 (pt)	2017-07-04	derivados de indol substituído
AU348425S (en)	2013-05-14	A loft bed